The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy

European Journal of Cancer

Volumn 76, Issue , 2017, Pages 167-182

  Brochez, Lieve ^a,b,c,d   Chevolet, Ines ^a,b,c   Kruse, Vibeke ^a,c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Dermatology Research Unit   (Belgium)

^c Immuno Oncology Network Ghent   (Belgium)

^d CANCER RESEARCH INSTITUTE GHENT CRIG   (Belgium)

Author keywords

Cancer; Epacadostat; IDO inhibition; Immune tolerance; Indoleamine 2 3 dioxygenase (IDO); Indoximod; Melanoma

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; CORTICOSTEROID; CYTOTOXIC AGENT; DOCETAXEL; DURVALUMAB; EPACADOSTAT; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INDOXIMOD; IPILIMUMAB; PEMBROLIZUMAB; PEPTIDE VACCINE; PLACEBO; 1-METHYLTRYPTOPHAN; ENZYME INHIBITOR; OXIME; SULFONAMIDE; TRYPTOPHAN;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; BLOOD; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RESEARCH; CANCER THERAPY; CHEMOTHERAPY INDUCED ANEMIA; COLORECTAL CANCER; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; MALIGNANT NEOPLASM; MELANOMA; NAUSEA; NON SMALL CELL LUNG CANCER; NONHUMAN; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TISSUES; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NEOPLASMS; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASMS; OXIMES; SULFONAMIDES; T-LYMPHOCYTES; TRYPTOPHAN;

EID: 85015363472     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.01.011     Document Type: Review

References (115)

1. [1] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
2. [2] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
3. [3] Larkin, J., Hodi, F.S., Wolchok, J.D., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 1270–1271.
4. [4] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
5. [5] Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
6. [6] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
7. [7] Theate, I., van Baren, N., Pilotte, L., Moulin, P., Larrieu, P., Renauld, J.C., et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 3 (2015), 161–172.
8. [8] Dai, X., Zhu, B.T., Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions. J Histochem Cytochem 58 (2010), 17–28.
9. [9] Chon, S.Y., Hassanain, H.H., Gupta, S.L., Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem 271 (1996), 17247–17252.
10. [10] Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3 (2002), 1097–1101.
11. [11] Babcock, T.A., Carlin, J.M., Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 12 (2000), 588–594.
12. [12] MacKenzie, C.R., Hadding, U., Daubener, W., Interferon-gamma-induced activation of indoleamine 2,3-dioxygenase in cord blood monocyte-derived macrophages inhibits the growth of group B streptococci. J Infect Dis 178 (1998), 875–878.
13. [13] Berthon, C., Fontenay, M., Corm, S., Briche, I., Allorge, D., Hennart, B., et al. Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leuk Res 37 (2013), 573–579.
14. [14] Munn, D.H., Sharma, M.D., Baban, B., Harding, H.P., Zhang, Y., Ron, D., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22 (2005), 633–642.
15. [15] Stevens, E.A., Mezrich, J.D., Bradfield, C.A., The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology 127 (2009), 299–311.
16. [16] Nguyen, N.T., Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A 107 (2010), 19961–19966.
17. [17] Mezrich, J.D., Fechner, J.H., Zhang, X., Johnson, B.P., Burlingham, W.J., Bradfield, C.A., An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185 (2010), 3190–3198.
18. [18] Murray, M.F., The human indoleamine 2,3-dioxygenase gene and related human genes. Curr Drug Metab 8 (2007), 197–200.
19. [19] Ball, H.J., Sanchez-Perez, A., Weiser, S., Austin, C.J., Astelbauer, F., Miu, J., et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396 (2007), 203–213.
20. [20] Metz, R., Duhadaway, J.B., Kamasani, U., Laury-Kleintop, L., Muller, A.J., Prendergast, G.C., Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 67 (2007), 7082–7087.
21. [21] Lob, S., Konigsrainer, A., Schafer, R., Rammensee, H.G., Opelz, G., Terness, P., Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111 (2008), 2152–2154.
22. [22] Thackray, S.J., Mowat, C.G., Chapman, S.K., Exploring the mechanism of tryptophan 2,3-dioxygenase. Biochem Soc Trans 36 (2008), 1120–1123.
23. [23] Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolusic, E., Frederick, R., et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A 109 (2012), 2497–2502.
24. [24] Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I., Conway, S.J., Marshall, B., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998), 1191–1193.
25. [25] Ferdinande, L., Demetter, P., Perez-Novo, C., Waeytens, A., Taildeman, J., Rottiers, I., et al. Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2,3-dioxygenase. Int J Immunopathol Pharmacol 21 (2008), 289–295.
26. [26] Matteoli, G., Mazzini, E., Iliev, I.D., Mileti, E., Fallarino, F., Puccetti, P., et al. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut 59 (2010), 595–604.
27. [27] Odemuyiwa, S.O., Ebeling, C., Duta, V., Abel, M., Puttagunta, L., Cravetchi, O., et al. Tryptophan catabolites regulate mucosal sensitization to ovalbumin in respiratory airways. Allergy 64 (2009), 488–492.
28. [28] Liu, H., Liu, L., Fletcher, B.S., Visner, G.A., Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am J Respir Crit Care Med 173 (2006), 566–572.
29. [29] Guillonneau, C., Hill, M., Hubert, F.X., Chiffoleau, E., Herve, C., Li, X.L., et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 117 (2007), 1096–1106.
30. [30] Swanson, K.A., Zheng, Y., Heidler, K.M., Mizobuchi, T., Wilkes, D.S., CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol 30 (2004), 311–318.
31. [31] Mellor, A.L., Baban, B., Chandler, P., Marshall, B., Jhaver, K., Hansen, A., et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171 (2003), 1652–1655.
32. [32] Yu, J., Sun, J., Wang, S.E., Li, H., Cao, S., Cong, Y., et al. Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol, 2011, 2011, 469135.
33. [33] Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12 (2006), 1144–1151.
34. [34] Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 95 (2006), 1555–1561.
35. [35] Ino, K., Yamamoto, E., Shibata, K., Kajiyama, H., Yoshida, N., Terauchi, M., et al. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14 (2008), 2310–2317.
36. [36] Muller, A.J., DuHadaway, J.B., Donover, P.S., Sutanto-Ward, E., Prendergast, G.C., Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11 (2005), 312–319.
37. [37] Cochran, A.J., Huang, R.R., Lee, J., Itakura, E., Leong, S.P., Essner, R., Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6 (2006), 659–670.
38. [38] Chevolet, I., Speeckaert, R., Haspeslagh, M., Neyns, B., Kruse, V., Schreuer, M., et al. Peri-tumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?. Br J Dermatol 171:5 (2014), 987–995.
39. [39] Munn, D.H., Sharma, M.D., Lee, J.R., Jhaver, K.G., Johnson, T.S., Keskin, D.B., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297 (2002), 1867–1870.
40. [40] Munn, D.H., Sharma, M.D., Hou, D., Baban, B., Lee, J.R., Antonia, S.J., et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114 (2004), 280–290.
41. [41] Chevolet, I., Speeckaert, R., Schreuer, M., Neyns, B., Krysko, O., Bachert, C., et al. Characterization of the immune network of IDO, tryptophan metabolism, PD-L1, and in circulating immune cells in melanoma. Oncoimmunology, 4, 2015, e982382.
42. [42] Chevolet, I., Speeckaert, R., Schreuer, M., Neyns, B., Krysko, O., Bachert, C., et al. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med, 13, 2015, 9.
43. [43] Ozaki, Y., Edelstein, M.P., Duch, D.S., Induction of indoleamine 2,3-dioxygenase—a mechanism of the antitumor-activity of interferon-gamma. P Natl Acad Sci USA 85 (1988), 1242–1246.
44. [44] Takikawa, O., Kuroiwa, T., Yamazaki, F., Kido, R., Mechanism of interferon-gamma action—characterization of indoleamine 2,3-dioxygenase in cultured human-cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 263 (1988), 2041–2048.
45. [45] Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., Parmentier, N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003), 1269–1274.
46. [46] Yen, M.C., Lin, C.C., Chen, Y.L., Huang, S.S., Yang, H.J., Chang, C.P., et al. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 15 (2009), 641–649.
47. [47] Huang, T.T., Yen, M.C., Lin, C.C., Weng, T.Y., Chen, Y.L., Lin, C.M., et al. Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. Cancer Sci 102 (2011), 2214–2220.
48. [48] Holmgaard, R.B., Zamarin, D., Munn, D.H., Wolchok, J.D., Allison, J.P., Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 210 (2013), 1389–1402.
49. [49] Beatty, G.L., O'Dwyer, P.J., Clark, J., Shi, J.G., Newton, R.C., Schaub, R., et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J Clin Oncol, 31, 2013.
50. [50] Gibney, G.T., Hamid, O., Gangadhar, T.C., Lutzky, J., Olszanski, A.J., Gajewski, T., et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol, 32, 2014.
51. [51] Komrokji, R.S., Wei, S., Mailloux, A.W., Zhang, L., Padron, E., Lancet, J.E., et al. A phase II study to determine the safety and efficacy of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO) enzyme INCB024360 in patients with myelodysplastic syndromes. Blood, 124, 2014.
52. [52] Soliman, H.H., Antonia, S., Sullivan, D., Vanahanian, N., Link, C., Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). J Clin Oncol, 27, 2009.
53. [53] Soliman, H.H., Jackson, E., Neuger, T., Dees, E.C., Harvey, R.D., Han, H., et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 5 (2014), 8136–8146.
54. [54] Iversen, T.Z., Engell-Noerregaard, L., Ellebaek, E., Andersen, R., Larsen, S.K., Bjoern, J., et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 20 (2014), 221–232.
55. [55] Andersen, M.H., Svane, I.M., Indoleamine 2,3-dioxygenase vaccination. Oncoimmunology, 4, 2015, e983770.
56. [56] Yeung, A.W., Terentis, A.C., King, N.J., Thomas, S.R., Role of indoleamine 2,3-dioxygenase in health and disease. Clin Sci (Lond) 129 (2015), 601–672.
57. [57] Hoyo-Becerra, C., Schlaak, J.F., Hermann, D.M., Insights from interferon-alpha-related depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun 42 (2014), 222–231.
58. [58] Capuron, L., Ravaud, A., Neveu, P.J., Miller, A.H., Maes, M., Dantzer, R., Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatr 7 (2002), 468–473.
59. [59] Prendergast, G.C., Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27 (2008), 3889–3900.
60. [60] Chevolet, I., Schreuer, M., Speeckaert, R., Neyns, B., Hoorens, I., van Geel, N., et al. Systemic immune changes associated with adjuvant interferon-alpha2b-therapy in stage III melanoma patients: failure at the effector phase?. Melanoma Res 25 (2015), 357–361.
61. [61] Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med, 5, 2013 200ra116.
62. [62] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
63. [63] Gao, Y.F., Peng, R.Q., Li, J., Ding, Y., Zhang, X., Wu, X.J., et al. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med, 7, 2009, 71.
64. [64] Engin, A., Gonul, I.I., Engin, A.B., Karamercan, A., Dincel, A.S., Dursun, A., Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma. World J Gastroenterol 22 (2016), 3592–3601.
65. [65] Ferdinande, L., Decaestecker, C., Verset, L., Mathieu, A., Moles Lopez, X., Negulescu, A.M., et al. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 106 (2012), 141–147.
66. [66] Galon, J., Mlecnik, B., Bindea, G., Angell, H.K., Berger, A., Lagorce, C., et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 232 (2014), 199–209.
67. [67] Moon, Y.W., Hajjar, J., Hwu, P., Naing, A., Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer, 3, 2015.
68. [68] Fukuno, K., Hara, T., Tsurumi, H., Shibata, Y., Mabuchi, R., Nakamura, N., et al. Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in patients with acute myeloid leukemia and intermediate-risk cytogenetics. Leuk Lymphoma, 2014, 1–25.
69. [69] Chamuleau, M.E., van de Loosdrecht, A.A., Hess, C.J., Janssen, J.J., Zevenbergen, A., Delwel, R., et al. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 93 (2008), 1894–1898.
70. [70] Corm, S., Berthon, C., Imbenotte, M., Biggio, V., Lhermitte, M., Dupont, C., et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk Res 33 (2009), 490–494.
71. [71] Folgiero, V., Goffredo, B.M., Filippini, P., Masetti, R., Bonanno, G., Caruso, R., et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget 5 (2014), 2052–2064.
72. [72] Mabuchi, R., Hara, T., Matsumoto, T., Shibata, Y., Nakamura, N., Nakamura, H., et al. High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. Leuk Lymphoma 57 (2016), 92–98.
73. [73] Chen, J.Y., Li, C.F., Kuo, C.C., Tsai, K.K., Hou, M.F., Hung, W.C., Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res, 16, 2014, 410.
74. [74] Sakurai, K., Fujisaki, S., Nagashima, S., Maeda, T., Tomita, R., Suzuki, S., et al. [Indoleamine 2, 3-dioxygenase activity for breast cancer patients with recurrence 5 or more years after surgery]. Gan To Kagaku Ryoho 40 (2013), 1590–1592.
75. [75] Soliman, H., Rawal, B., Fulp, J., Lee, J.H., Lopez, A., Bui, M.M., et al. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immunother 62 (2013), 829–837.
76. [76] Jacquemier, J., Bertucci, F., Finetti, P., Esterni, B., Charafe-Jauffret, E., Thibult, M.L., et al. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 130 (2012), 96–104.
77. [77] Ferns, D.M., Kema, I.P., Buist, M.R., Nijman, H.W., Kenter, G.G., Jordanova, E.S., Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival. Oncoimmunology, 4, 2015.
78. [78] Inaba, T., Ino, K., Kajiyama, H., Shibata, K., Yamamoto, E., Kondo, S., et al. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol Oncol 117 (2010), 423–428.
79. [79] Huang, A., Fuchs, D., Widner, B., Glover, C., Henderson, D.C., Allen-Mersh, T.G., Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 86 (2002), 1691–1696.
80. [80] de Jong, R.A., Kema, I.P., Boerma, A., Boezen, H.M., van der Want, J.J., Gooden, M.J., et al. Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol Oncol 126 (2012), 474–480.
81. [81] Jia, Y.L., Wang, H.Y., Wang, Y., Wang, T.T., Wang, M., Ma, M., et al. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer 137 (2015), 1095–1106.
82. [82] Zhang, G., Liu, W.L., Zhang, L., Wang, J.Y., Kuang, M.H., Liu, P., et al. Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma. Clin Dev Immunol, 2011, 2011, 384726.
83. [83] Kim, J.W., Nam, K.H., Ahn, S.H., Park, D.J., Kim, H.H., Kim, S.H., et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 19 (2016), 42–52.
84. [84] Zhang, R.P., Liu, H., Li, F.X., Li, H., Yu, J.P., Ren, X.B., The correlation between the subsets of tumor infiltrating memory T cells and the expression of indoleamine 2,3-dioxygenase in gastric cancer. Dig Dis Sci 58 (2013), 3494–3502.
85. [85] Zhai, L.J., Dey, M., Lauing, K.L., Gritsina, G., Kaur, R., Lukas, R.V., et al. The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. J Clin Neurosci 22 (2015), 1964–1968.
86. [86] Mitsuka, K., Kawataki, T., Satoh, E., Asahara, T., Horikoshi, T., Kinouchi, H., Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery 72 (2013), 1031–1038 discussion 8–9.
87. [87] Wainwright, D.A., Balyasnikova, I.V., Chang, A.L., Ahmed, A.U., Moon, K.S., Auffinger, B., et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18 (2012), 6110–6121.
88. [88] Pan, K., Wang, H., Chen, M.S., Zhang, H.K., Weng, D.S., Zhou, J., et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 134 (2008), 1247–1253.
89. [89] Ishio, T., Goto, S., Tahara, K., Tone, S., Kawano, K., Kitano, S., Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 19 (2004), 319–326.
90. [90] Choe, J.Y., Yun, J.Y., Jeon, Y.K., Kim, S.H., Park, G., Huh, J.R., et al. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer, 14, 2014, 335.
91. [91] Ye, J., Liu, H., Hu, Y., Li, P., Zhang, G., Li, Y., Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch 462 (2013), 73–81.
92. [92] Creelan, B.C., Antonia, S., Bepler, G., Garrett, T.J., Simon, G.R., Soliman, H.H., Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology, 2, 2013, e23428.
93. [93] Suzuki, Y., Suda, T., Furuhashi, K., Suzuki, M., Fujie, M., Hahimoto, D., et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67 (2010), 361–365.
94. [94] Karanikas, V., Zamanakou, M., Kerenidi, T., Dahabreh, J., Hevas, A., Nakou, M., et al. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 6 (2007), 1258–1262.
95. [95] Astigiano, S., Morandi, B., Costa, R., Mastracci, L., D'Agostino, A., Ratto, G.B., et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 7 (2005), 390–396.
96. [96] Pelak, M.J., Snietura, M., Lange, D., Nikiel, B., Pecka, K.M., The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor B and interferon gamma in metastatic lymph nodes in malignant melanoma. Pol J Pathol 66 (2015), 376–382.
97. [97] Ryan, M., Crow, J., Kahmke, R., Fisher, S.R., Su, Z., Lee, W.T., FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients. Am J Otolaryngol 35:6 (2014), 689–694.
98. [98] Speeckaert, R., Vermaelen, K., van Geel, N., Autier, P., Lambert, J., Haspeslagh, M., et al. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer 48 (2012), 2004–2011.
99. [99] Brody, J.R., Costantino, C.L., Berger, A.C., Sato, T., Lisanti, M.P., Yeo, C.J., et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 8 (2009), 1930–1934.
100. [100] Weinlich, G., Murr, C., Richardsen, L., Winkler, C., Fuchs, D., Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214 (2007), 8–14.
101. [101] Nam, S.J., Kim, S., Paik, J.H., Kim, T.M., Heo, D.S., Kim, C.W., et al. An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. Leuk Lymphoma, 2016, 1–5.
102. [102] Liu, X.Q., Lu, K., Feng, L.L., Ding, M., Gao, J.M., Ge, X.L., et al. Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration. Leuk Lymphoma 55 (2014), 405–414.
103. [103] Ninomiya, S., Hara, T., Tsurumi, H., Hoshi, M., Kanemura, N., Goto, N., et al. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 90 (2011), 409–416.
104. [104] Yoshikawa, T., Hara, T., Tsurumi, H., Goto, N., Hoshi, M., Kitagawa, J., et al. Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 84 (2010), 304–309.
105. [105] Laimer, K., Troester, B., Kloss, F., Schafer, G., Obrist, P., Perathoner, A., et al. Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 47 (2011), 352–357.
106. [106] Urakawa, H., Nishida, Y., Nakashima, H., Shimoyama, Y., Nakamura, S., Ishiguro, N., Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 26 (2009), 1005–1012.
107. [107] Inaba, T., Ino, K., Kajiyama, H., Yamamoto, E., Shibata, K., Nawa, A., et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 115 (2009), 185–192.
108. [108] Takao, M., Okamoto, A., Nikaido, T., Urashima, M., Takakura, S., Saito, M., et al. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 17 (2007), 1333–1339.
109. [109] Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11 (2005), 6030–6039.
110. [110] Yuan, F., Liu, Y., Fu, X., Chen, J., Indoleamine-pyrrole 2,3-dioxygenase might be a prognostic biomarker for patients with renal cell carcinoma. Zhong Nan Da Xue Xue Bao Yi Xue Ban 37 (2012), 649–655.
111. [111] Riesenberg, R., Weiler, C., Spring, O., Eder, M., Buchner, A., Popp, T., et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 13 (2007), 6993–7002.
112. [112] Moretti, S., Menicali, E., Voce, P., Morelli, S., Cantarelli, S., Sponziello, M., et al. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. J Clin Endocr Metab 99 (2014), E832–E840.
113. [113] de Jong, R.A., Toppen, N.L., Ten Hoor, K.A., Boezen, H.M., Kema, I.P., Hollema, H., et al. Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma. Gynecol Oncol 125 (2012), 186–193.
114. [114] Sznurkowski, J.J., Zawrocki, A., Emerich, J., Sznurkowska, K., Biernat, W., Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests. Gynecol Oncol 122 (2011), 307–312.
115. [115] Bjoern, J., Iversen, T.Z., Nitschke, N.J., Andersen, M.H., Svane, I.M., Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy 18:8 (2016), 1043–1055.